Press Releases

YEAR
Toggle Summary Nabriva Therapeutics Announces Acceptance of New Drug Applications by the FDA for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
-PDUFA action date set for August 19, 2019- DUBLIN, Ireland , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that
View HTML
Toggle Summary Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on January 23, 2019
DUBLIN, Ireland , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, today announced that the Company will webcast its Analyst
View HTML
Toggle Summary Nabriva Therapeutics Provides Update on PDUFA Date for Intravenous CONTEPO™
-PDUFA action date now set for April 30, 2019- DUBLIN, Ireland , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced
View HTML
Toggle Summary Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections by FDA
-PDUFA action date set for June 30, 2019- DUBLIN, Ireland , Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that
View HTML
Toggle Summary Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan
-Financing Strengthens Cash Position Ahead of Two Potential Product Launches in 2019- DUBLIN, Ireland , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to
View HTML
Toggle Summary Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
DUBLIN, Ireland , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced the submission of two New Drug Applications
View HTML
Toggle Summary Nabriva Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that Ted Schroeder ,
View HTML
Toggle Summary Nabriva Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
- New Drug Application for CONTEPO ™ submitted to FDA in October 2018 - - Company preparing for potential commercialization of two, first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - DUBLIN, Ireland , Nov.
View HTML
Toggle Summary Nabriva Therapeutics Completes Submission of New Drug Application to U.S. Food and Drug Administration for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections
DUBLIN, Ireland , Nov. 01, 2018 (GLOBE NEWSWIRE) --   Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced it has submitted a New Drug Application (NDA)
View HTML
Toggle Summary Nabriva Therapeutics to Present Data at ID Week Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPO™ (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs)
New data continue to support lefamulin and CONTEPO as potential first-in-class antibiotics in the United States that target the most common causative pathogens of CABP and cUTI, including multi-drug resistant (MDR) strains DUBLIN, Ireland , Sept. 28, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics
View HTML

For Media Inquiries

PR@nabriva.com


For Investor Relations

David Garrett
Vice President, Corporate Controller and Head of Investor Relations
Nabriva Therapeutics plc

E-mail: david.garrett@nabriva.com